Breaking News Instant updates and real-time market news.

ILMN

Illumina

$138.00

0.83 (0.61%)

, RHHBY

Roche

$29.69

-0.02 (-0.07%)

09:53
10/17/16
10/17
09:53
10/17/16
09:53

Illumina pullback could speed up, or 'blow up,' a takeover bid, Harrington says

In a new interview with Tip TV Finance, Betaville's Ben Harrington said the pullback in shares of Illumina (ILMN) following its profit warning could make the company more palatable as a takeover target, possibly for Roche (RHHBY). In a previous interview with Tip TV, Harrington also discussed rumors that Roche was considering revisiting a bid for Illumina. Reference Link

ILMN

Illumina

$138.00

0.83 (0.61%)

RHHBY

Roche

$29.69

-0.02 (-0.07%)

  • 19

    Oct

  • 01

    Nov

  • 06

    Nov

  • 10

    Nov

ILMN Illumina
$138.00

0.83 (0.61%)

10/11/16
PIPR
10/11/16
NO CHANGE
Target $150
PIPR
Overweight
Illumina selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst William Quirk recommends using today's selloff in shares of Illumina as a buying opportunity. The stock traded down 24% last night after the company reported preliminary Q3 revenue of $607M, below the Street's $628.3M estimate. A lower number of HiSeq 2500/4000 installs as well as a HiSeq X Ten placement slip drove the revenue miss, Quirk tells investors in a research note. He notes, however, that his HiSeq X checks found the pipeline remains "very strong" at 95 systems, with a majority driven by the Chinese precision medicine program. He views $130 as a "technical floor" for the shares and dropped his price target for Illumina to $150 from $163. Quirk keeps an Overweight rating on the name.
10/11/16
SBSH
10/11/16
DOWNGRADE
Target $140
SBSH
Neutral
Illumina downgraded to Neutral from Buy at Citi
Citi analyst Daniel Arias downgraded Illumina to Neutral saying last night's preannouncement marked the company's fourth miss in six quarters. "Forecasting capabilities have clearly diminished," Arias tells investors in a research note. He lowered his price target for the shares to $140 and thinks the stock could hit the $110-$120 range today. Illumina is trading down $48.59, or 26%, to $136.26 in the pre-market.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RHHBY Roche
$29.69

-0.02 (-0.07%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

07:47
04/26/17
04/26
07:47
04/26/17
07:47
General news
Futures little changed as earnings parade marches on »

Stock futures are off…

CAT

Caterpillar

$104.42

7.61 (7.86%)

07:46
04/26/17
04/26
07:46
04/26/17
07:46
Recommendations
Caterpillar analyst commentary  »

Caterpillar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    Jun

MCD

McDonald's

$141.70

7.47 (5.57%)

07:46
04/26/17
04/26
07:46
04/26/17
07:46
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SAP

SAP

$102.13

0.75 (0.74%)

07:45
04/26/17
04/26
07:45
04/26/17
07:45
Downgrade
SAP rating change  »

SAP downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

FCAU

Fiat Chrysler

$10.54

-0.02 (-0.19%)

07:44
04/26/17
04/26
07:44
04/26/17
07:44
Earnings
Fiat Chrysler confirms FY17 guidance for revenue, EBIT »

The Group confirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$59.29

0.64 (1.09%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Recommendations
Baker Hughes analyst commentary  »

Baker Hughes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SYBT

S.Y. Bancorp

$42.30

0.85 (2.05%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Earnings
S.Y. Bancorp reports Q1 EPS 47c, consensus 45c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

CBOE

CBOE Holdings

$84.16

0.32 (0.38%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Syndicate
CBOE Holdings 2.25M share Block Trade; price range $83.25-$83.75 »

Jefferies is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

FCAU

Fiat Chrysler

$10.54

-0.02 (-0.19%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Earnings
Fiat Chrysler reports Q1 adjusted EBIT EU1.54B, consensus EU1.44B »

Reports Q1 revenues of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$54.31

0.5 (0.93%)

07:42
04/26/17
04/26
07:42
04/26/17
07:42
Recommendations
TSYS analyst commentary  »

TSYS price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$19.45

-0.3083 (-1.56%)

07:42
04/26/17
04/26
07:42
04/26/17
07:42
Periodicals
Embraer partners with Uber to develop electric vehicles, Reuters reports »

Brazilian planemaker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:41
04/26/17
04/26
07:41
04/26/17
07:41
Earnings
Silgan Holdings raises FY17 adj. EPS view to $3.20-$3.40 from $3.15-$3.35 »

Silgan Holdings increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

SAH

Sonic Automotive

07:41
04/26/17
04/26
07:41
04/26/17
07:41
Earnings
Sonic Automotive reports Q1 adjusted EPS 23c, consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 20

    Jun

MMM

3M

07:40
04/26/17
04/26
07:40
04/26/17
07:40
Recommendations
3M analyst commentary  »

3M price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 31

    May

07:40
04/26/17
04/26
07:40
04/26/17
07:40
General news
FX Update: The yen rebounded from fresh lows »

FX Update: The yen…

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:39
04/26/17
04/26
07:39
04/26/17
07:39
Earnings
Breaking Earnings news story on Silgan Holdings »

Silgan Holdings sees Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

IMAX

IMAX

07:39
04/26/17
04/26
07:39
04/26/17
07:39
Hot Stocks
IMAX and PVR Cinemas sign agreement for five theaters in India »

IMAX and PVR, the largest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEL

American Equity

$24.63

0.53 (2.20%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Initiation
American Equity initiated  »

American Equity initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

EADSY

Airbus

$20.22

0.2 (1.00%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Periodicals
China Southern to buy $6B in widebody jets from Airbus, Bloomberg reports »

China Southern Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Earnings
Silgan Holdings reports Q1 adj. EPS 62c, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

TROW

T. Rowe Price

$69.59

-3.04 (-4.19%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Downgrade
T. Rowe Price rating change  »

T. Rowe Price downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

TOSBF

Toshiba, also use TOSYY

$1.96

0.024 (1.24%)

, TOSYY

Toshiba, also use TOSBF

$11.76

0.27 (2.35%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Periodicals
Toshiba plans to replace auditor PwC, Reuters says »

Toshiba is planning to…

TOSBF

Toshiba, also use TOSYY

$1.96

0.024 (1.24%)

TOSYY

Toshiba, also use TOSBF

$11.76

0.27 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$141.70

7.47 (5.57%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$183.51

1.45 (0.80%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Hot Stocks
Boeing backs FY17 CapEx view approximately $2.3B »

Cuts FY17 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 31

    May

ESRX

Express Scripts

$60.01

-7.24 (-10.77%)

, ANTM

Anthem

$172.46

4.05 (2.40%)

07:37
04/26/17
04/26
07:37
04/26/17
07:37
Recommendations
Express Scripts, Anthem analyst commentary  »

Express Scripts should be…

ESRX

Express Scripts

$60.01

-7.24 (-10.77%)

ANTM

Anthem

$172.46

4.05 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 18

    May

  • 06

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.